Breast cancer cell targeting by prenylation inhibitors elucidated in living animals with a bioluminescence reporter

Clinical Cancer Research

Volumn 18, Issue 15, 2012, Pages 4136-4144

  Chinault, Sharon L ^a   Prior, Julie L ^b   Kaltenbronn, Kevin M ^a   Penly, Anya ^a   Weilbaecher, Katherine N ^a   Piwnica Worms, David ^b   Blumer, Kendall J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; GGTI 298; GREEN FLUORESCENT PROTEIN; PRENYLTRANSFERASE INHIBITOR; SIMVASTATIN; TRANSFERASE INHIBITOR; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLUMINESCENCE; BREAST CANCER; CONTROLLED STUDY; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; IMAGING; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PRENYLATION; TUMOR CELL;

ALKYL AND ARYL TRANSFERASES; ANIMALS; BENZAMIDES; BLOTTING, WESTERN; BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CLODRONIC ACID; DIPHOSPHONATES; FEMALE; GENES, REPORTER; GREEN FLUORESCENT PROTEINS; HEK293 CELLS; HUMANS; IMIDAZOLES; LUCIFERASES; LUMINESCENT MEASUREMENTS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; MICROSCOPY, CONFOCAL; MUTATION; PROTEIN PRENYLATION; RECOMBINANT FUSION PROTEINS; TRANSPLANTATION, HETEROLOGOUS;

EID: 84864420076     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0642     Document Type: Article

References (37)

1. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425-30.
2. Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, et al. Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci U S A 2001;98:5856-61. (Pubitemid 32435732)
3. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet 2000;356:1627-31.
4. Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM. Statins and cancer prevention. Nat Rev Cancer 2005;5:930-42. (Pubitemid 41766782)
5. Kavanagh KL, Guo K, Dunford JE, Wu X, Knapp S, Ebetino FH, et al. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci U S A 2006;103:7829-34.
6. Roelofs AJ, Thompson K, Gordon S, Rogers MJ. Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 2006;12:6222s-30s. (Pubitemid 44703794)
7. Russell RG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999;25:97-106. (Pubitemid 29322070)
8. Clezardin P, Ebetino FH, Fournier PG. Bisphosphonates and cancerinduced bone disease: beyond their antiresorptive activity. Cancer Res 2005;65:4971-4. (Pubitemid 40827299)
9. Daubine F, Le Gall C, Gasser J, Green J, Clezardin P. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst 2007;99:322-30. (Pubitemid 47073494)
10. Winter MC, Coleman RE. Bisphosphonates in breast cancer: teaching an old dog new tricks. Curr Opin Oncol 2009;21:499-506.
11. Coleman RE, Marshall H, Cameron D, Dodwell D, BurkinshawR, Keane M, et al. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 2011;365:1396-405.
12. Philips MR, Cox AD. Geranylgeranyltransferase I as a target for anticancer drugs. J Clin Invest 2007;117:1223-5.
13. Tsimberidou AM, Chandhasin C, Kurzrock R. Farnesyltransferase inhibitors: where are we now? Expert Opin Investig Drugs 2010;19:1569-80.
14. Berndt N, Hamilton AD, Sebti SM. Targeting protein prenylation for cancer therapy. Nat Rev Cancer 2011;11:775-91.
15. Young SG, Meta M, Yang SH, Fong LG. Prelamin A farnesylation and progeroid syndromes. J Biol Chem 2006;281:39741-5. (Pubitemid 46041777)
16. Carrico D, Ohkanda J, Kendrick H, Yokoyama K, Blaskovich MA, Bucher CJ, et al. In vitro and in vivo antimalarial activity of peptidomimetic protein farnesyltransferase inhibitors with improved membrane permeability. Bioorg Med Chem 2004;12:6517-26. (Pubitemid 39535174)
17. Chakrabarti D, Da Silva T, Barger J, Paquette S, Patel H, Patterson S, et al. Protein farnesyltransferase and protein prenylation in Plasmodium falciparum. J Biol Chem 2002;277:42066-73. (Pubitemid 35257521)
18. Hirbe AC, Roelofs AJ, Floyd DH, Deng H, Becker SN, Lanigan LG, et al. The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts. Bone 2009;44:908-16.
19. Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000;82:1459-68. (Pubitemid 30175914)
20. Berndt N, Sebti SM. Measurement of protein farnesylation and geranylgeranylation in vitro, in cultured cells and in biopsies, and the effects of prenyl transferase inhibitors. Nat Protoc 2011;6:1775-91.
21. Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Wieser R, et al. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 1999;103:197-206. (Pubitemid 29053137)
22. Uluckan O, Becker SN, Deng H, Zou W, Prior JL, Piwnica-Worms D, et al. CD47 regulates bone mass and tumor metastasis to bone. Cancer Res 2009;69:3196-204.
23. Gross S, Piwnica-Worms D. Real-time imaging of ligand-induced IKK activation in intact cells and in living mice. Nat Methods 2005;2:607-14. (Pubitemid 41086852)
24. Winter-Vann AM, Casey PJ. Post-prenylation-processing enzymes as new targets in oncogenesis. Nat Rev Cancer 2005;5:405-12. (Pubitemid 40637832)
25. Lerner EC, Zhang TT, Knowles DB, Qian Y, Hamilton AD, Sebti SM. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines. Oncogene 1997;15:1283-8. (Pubitemid 27429743)
26. Gao L, Deng H, Zhao H, Hirbe A, Harding J, Ratner L, et al. HTLV-1 Tax transgenic mice develop spontaneous osteolytic bone metastases prevented by osteoclast inhibition. Blood 2005;106:4294-302. (Pubitemid 41775939)
27. van der Pluijm G, Que I, Sijmons B, Buijs JT, Lowik CW, Wetterwald A, et al. Interference with the microenvironmental support impairs the de novo formation of bone metastases in vivo. Cancer Res 2005;65:7682-90. (Pubitemid 41297242)
28. Sebti SM, Hamilton AD. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene 2000;19:6584-93. (Pubitemid 32197696)
29. Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S, et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 2002;42:1228-36. (Pubitemid 35205058)
30. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991;88:2095-105.
31. Coleman RE, Winter MC, Cameron D, Bell R, Dodwell D, Keane MM, et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct antitumour activity in breast cancer. Br J Cancer 2010;102:1099-105.
32. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Postlberger S, Menzel C, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009;360:679-91.
33. Zhang K, Kim S, Cremasco V, Hirbe AC, Collins L, Piwnica-Worms D, et al. CD8+ T cells regulate bone tumor burden independent of osteoclast resorption. Cancer Res 2011;71:4799-808.
34. Mantovani A, Marchesi F, Porta C, Sica A, Allavena P. Inflammation and cancer: breast cancer as a prototype. Breast 2007;16 Suppl 2:S27-33.
35. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009;182:4499-506.
36. Sinha P, Clements VK, Miller S, Ostrand-Rosenberg S. Tumor immunity: a balancing act between T cell activation, macrophage activation and tumor-induced immune suppression. Cancer Immunol Immunother 2005;54:1137-42. (Pubitemid 41396817)
37. Sun J, Qian Y, Hamilton AD, Sebti SM. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts. Oncogene 1998;16:1467-73. (Pubitemid 28151853)